<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the long-term follow up of 49 patients (pts) enrolled on plerixafor compassionate use protocol </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-seven pts (76%) had failed one previous mobilization attempt, while 12 (24%) had failed two or more previous attempts </plain></SENT>
<SENT sid="2" pm="."><plain>Using the combination of plerixafor and granulocyte colony-stimulating factor, we collected2.5 × 10(6) CD34+cells/kg in 33 pts (67%) </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-three of the 49 pts proceeded to an auto-SCT (ASCT) </plain></SENT>
<SENT sid="4" pm="."><plain>The median days to WBC and platelet engraftment were 11 (range, 9-13 days) and 16 (range, 11-77 days) days post ASCT, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The median WBC count, Hb and platelet counts 1 year after ASCT were 4.7 × 10(9)/L, 12.2 g/dL and 109 × 10(9)/L, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>With median follow up of 42 months (range &lt;1-54 months), 21 pts had evidence of disease progression </plain></SENT>
<SENT sid="7" pm="."><plain>Five pts developed <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at median of 29 months post ASCT </plain></SENT>
<SENT sid="8" pm="."><plain>The cumulative incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at 42 months was 17% (95% confidence interval, 6 to 32%) </plain></SENT>
<SENT sid="9" pm="."><plain>Development of <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in pts proceeding to ASCT after plerixafor mobilization needs to be studied further in a larger cohort.Bone Marrow Transplantation advance online publication, 11 March 2013; doi:10.1038/bmt.2013.10 </plain></SENT>
</text></document>